Dr LUPORSI Elisabeth

Predisposition to ALL and Solid Tumors Rather Than Bone Marrow Failure in -Associated Fanconi Anemia.

Pegoraro F, Larcher L, Kim R, Pagès M, Passet M, Caye-Eude A, Fahd M, Brethon B, Hernandez L, Vasquez N, Da Costa M, Auger N, Lachaud C, de Tersant M, Luporsi E, Sébert M, Dalle JH, Peffault de Latour R, Clappier E, Stoppa-Lyonnet D, Leblanc T, Paillard C, Sicre de Fontbrune F, Soulier J

JCO Precis Oncol. 2026 03;10(3):e2501089

Screening Mammography and Breast Cancer: Variation in Risk with Rare Deleterious or Predicted Deleterious Variants in DNA Repair Genes.

Ribeiro-Guerra M, Dondon MG, Eon-Marchais S, Le Gal D, Beauvallet J, Mebirouk N, Belotti M, Cavaciuti E, Adenis-Lavignasse C, Audebert-Bellanger S, Berthet P, Bonadona V, Buecher B, Caron O, Cavaille M, Chiesa J, Colas C, Coupier I, Delnatte C, Dreyfus H, Fajac A, Fert-Ferrer S, Fricker JP, Gauthier-Villars M, Gesta P, Giraud S, Gladieff L, Lasset C, Lejeune-Dumoulin S, Limacher JM, Longy M, Lortholary A, Luporsi E, Maugard CM, Mortemousque I, Nambot S, Noguès C, Pujol P, Venat-Bouvet L, Soubrier F, Tinat J, Tardivon A, Lesueur F, Stoppa-Lyonnet D, Andrieu N

Cancers (Basel). 2025 03 21;17(7):

Content validation of an electronic remote toxicity management system in adult patients undergoing cancer treatment: a prospective longitudinal study on the QuestOnco application.

Longo R, Goetz C, Campitiello M, Plastino F, Egea J, Legros PO, Elnar AA, Meraihi S, Luporsi E, Noirez V

BMC Cancer. 2024 12 23;24(1):1568

[News in breast oncology genetics for female and male population].

Taris N, Luporsi E, Osada M, Thiblet M, Mathelin C

Gynecol Obstet Fertil Senol. 2024 01 6;:

French college of gynecologists and obstetricians (CNGOF) recommendations for clinical practice: Place of breast self-examination in screening strategies.

Lavoue V, Favier A, Franck S, Boutet G, Azuar AS, Brousse S, Golfier F, Uzan C, Vaysse C, Molière S, Boisserie-Lacroix M, Kermarrec E, Seror JY, Delpech Y, Luporsi É, Maugard CM, Taris N, Chabbert-Buffet N, Sabah J, Alghamdi K, Fritel X, Mathelin C

Breast. 2024 01 3;75:103619

[French College of Gynecologists and Obstetricians (CNGOF) recommendations for clinical practice. Place of breast self-examination in screening strategies].

Lavoué V, Favier A, Sophie F, Boutet G, Azuar AS, Brousse S, Golfier F, Uzan C, Vaysse C, Molière S, Boisserie-Lacroix M, Kermarrec E, Seror JY, Delpech Y, Luporsi É, Maugard CM, Taris N, Chabbert-Buffet N, Sabah J, Alghamdi K, Fritel X, Mathelin C

Gynecol Obstet Fertil Senol. 2023 08 29;:

Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.

Jiao Y, Truong T, Eon-Marchais S, Mebirouk N, Caputo SM, Dondon MG, Karimi M, Le Gal D, Beauvallet J, Le Floch É, Dandine-Roulland C, Bacq-Daian D, Olaso R, Albuisson J, Audebert-Bellanger S, Berthet P, Bonadona V, Buecher B, Caron O, Cavaillé M, Chiesa J, Colas C, Collonge-Rame MA, Coupier I, Delnatte C, De Pauw A, Dreyfus H, Fert-Ferrer S, Gauthier-Villars M, Gesta P, Giraud S, Gladieff L, Golmard L, Lasset C, Lejeune-Dumoulin S, Léoné M, Limacher JM, Lortholary A, Luporsi É, Mari V, Maugard CM, Mortemousque I, Mouret-Fourme E, Nambot S, Noguès C, Popovici C, Prieur F, Pujol P, Sevenet N, Sobol H, Toulas C, Uhrhammer N, Vaur D, Venat L, Boland-Augé A, Guénel P, Deleuze JF, Stoppa-Lyonnet D, Andrieu N, Lesueur F

Eur J Cancer. 2022 11 13;179:76-86

Iron deficiency screening is a key issue in chronic inflammatory diseases: A call for actions.

Cacoub P, Choukroun G, Cohen-Solal A, Luporsi E, Peyrin-Biroulet L, Peoc'h K, Andrieu V, Lasocki S, Puy H, Trochu JN

J Intern Med. 2022 Apr 24;:

Towards a Common Definition for the Diagnosis of Iron Deficiency in Chronic Inflammatory Diseases.

Cacoub P, Choukroun G, Cohen-Solal A, Luporsi E, Peyrin-Biroulet L, Peoc'h K, Andrieu V, Lasocki S, Puy H, Trochu JN

Nutrients. 2022 Feb 28;14(5):

[Techniques and complications of non-genetic risk reducing mastectomies: Guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)].

Mathelin C, Barranger E, Boisserie-Lacroix M, Boutet G, Brousse S, Chabbert-Buffet N, Coutant C, Daraï E, Delpech Y, Duraes M, Espié M, Golfier F, Hamy AS, Kermarrec E, Lavoué V, Lodi M, Luporsi É, Maugard C, Molière S, Seror JY, Taris N, Uzan C, Vaysse C, Fritel X

Gynecol Obstet Fertil Senol. 2021 Dec 15;:

[Non-genetic indications for risk reducing mastectomies: Guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)].

Mathelin C, Barranger E, Boisserie-Lacroix M, Boutet G, Brousse S, Chabbert-Buffet N, Coutant C, Daraï E, Delpech Y, Duraes M, Espié M, Fornecker L, Golfier F, Grosclaude P, Hamy AS, Kermarrec E, Lavoué V, Lodi M, Luporsi É, Maugard CM, Molière S, Seror JY, Taris N, Uzan C, Vaysse C, Fritel X

Gynecol Obstet Fertil Senol. 2021 Dec 14;:

Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation.

Ribeiro Guerra M, Coignard J, Eon-Marchais S, Dondon MG, Le Gal D, Beauvallet J, Mebirouk N, Belotti M, Caron O, Gauthier-Villars M, Coupier I, Buecher B, Lortholary A, Fricker JP, Gesta P, Noguès C, Faivre L, Berthet P, Luporsi E, Delnatte C, Bonadona V, Maugard CM, Pujol P, Lasset C, Longy M, Bignon YJ, Adenis-Lavignasse C, Venat-Bouvet L, Dreyfus H, Gladieff L, Mortemousque I, Audebert-Bellanger S, Soubrier F, Giraud S, Lejeune-Dumoulin S, Limacher JM, Chiesa J, Fajac A, Floquet A, Eisinger F, Tinat J, Fert-Ferrer S, Colas C, Frebourg T, Damiola F, Barjhoux L, Cavaciuti E, Mazoyer S, Tardivon A, Lesueur F, Stoppa-Lyonnet D, Andrieu N

Breast Cancer Res. 2021 Aug 3;23(1):79

Iron deficiency in patients with cancer: a prospective cross-sectional study.

Luporsi E, Turpin A, Massard V, Morin S, Chauffert B, Carnot A, Cacoub P,

BMJ Support Palliat Care. 2021 Jul 30;:

Gene and pathway level analyses of iCOGS variants highlight novel signalling pathways underlying familial breast cancer susceptibility.

Lonjou C, Eon-Marchais S, Truong T, Dondon MG, Karimi M, Jiao Y, Damiola F, Barjhoux L, Le Gal D, Beauvallet J, Mebirouk N, Cavaciuti E, Chiesa J, Floquet A, Audebert-Bellanger S, Giraud S, Frebourg T, Limacher JM, Gladieff L, Mortemousque I, Dreyfus H, Lejeune-Dumoulin S, Lasset C, Venat-Bouvet L, Bignon YJ, Pujol P, Maugard CM, Luporsi E, Bonadona V, Noguès C, Berthet P, Delnatte C, Gesta P, Lortholary A, Faivre L, Buecher B, Caron O, Gauthier-Villars M, Coupier I, Mazoyer S, Monraz LC, Kondratova M, Kuperstein I, Guénel P, Barillot E, Stoppa-Lyonnet D, Andrieu N, Lesueur F

Int J Cancer. 2020 Dec 24;:

Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET).

Vasseur A, Cabel L, Tredan O, Chevrier M, Dubot C, Lorgis V, Jacot W, Goncalves A, Debled M, Levy C, Ferrero JM, Jouannaud C, Luporsi E, Mouret-Reynier MA, Dalenc F, Lemonnier J, Savignoni A, Tanguy ML, Bidard FC, Pierga JY

Angiogenesis. 2019 Nov 26;:

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.

Jacot W, Cottu P, Berger F, Dubot C, Venat-Bouvet L, Lortholary A, Bourgeois H, Bollet M, Servent V, Luporsi E, Espié M, Guiu S, D'Hondt V, Dieras V, Sablin MP, Brain E, Neffati S, Pierga JY, Bidard FC

Breast Cancer Res.. 2019 Nov 14;21(1):121

A novel machine learning-derived decision tree including uPA/PAI-1 for breast cancer care.

Reix N, Lodi M, Jankowski S, Molière S, Luporsi E, Leblanc S, Scheer L, Ibnouhsein I, Benabu JC, Gabriele V, Guggiola A, Lessinger JM, Chenard MP, Alpy F, Bellocq JP, Neuberger K, Tomasetto C, Mathelin C

Clin. Chem. Lab. Med.. 2018 Dec 20;:

The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With or Mutations.

Terry MB, Liao Y, Kast K, Antoniou AC, McDonald JA, Mooij TM, Engel C, Nogues C, Buecher B, Mari V, Moretta-Serra J, Gladieff L, Luporsi E, Barrowdale D, Frost D, Henderson A, Brewer C, Evans DG, Eccles D, Cook J, Ong KR, Izatt L, Ahmed M, Morrison PJ, Dommering CJ, Oosterwijk JC, Ausems MGEM, Kriege M, Buys SS, Andrulis IL, John EM, Daly M, Friedlander M, McLachlan SA, Osorio A, Caldes T, Jakubowska A, Simard J, Singer CF, Tan Y, Olah E, Navratilova M, Foretova L, Gerdes AM, Roos-Blom MJ, Arver B, Olsson H, Schmutzler RK, Hopper JL, van Leeuwen FE, Goldgar D, Milne RL, Easton DF, Rookus MA, Andrieu N,

JNCI Cancer Spectr. 2018 Dec;2(4):pky078

Familial breast cancer and DNA repair genes: insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.

Girard E, Eon-Marchais S, Olaso R, Renault AL, Damiola F, Dondon MG, Barjhoux L, Goidin D, Meyer V, Le Gal D, Beauvallet J, Mebirouk N, Lonjou C, Coignard J, Marcou M, Cavaciuti E, Baulard C, Bihoreau MT, Cohen-Haguenauer O, Leroux D, Penet C, Fert-Ferrer S, Colas C, Frebourg T, Eisinger F, Adenis C, Fajac A, Gladieff L, Tinat J, Floquet A, Chiesa J, Giraud S, Mortemousque I, Soubrier F, Audebert-Bellanger S, Limacher JM, Lasset C, Lejeune-Dumoulin S, Dreyfus H, Bignon YJ, Longy M, Pujol P, Venat-Bouvet L, Bonadona V, Berthet P, Luporsi E, Maugard CM, Noguès C, Delnatte C, Fricker JP, Gesta P, Faivre L, Lortholary A, Buecher B, Caron O, Gauthier-Villars M, Coupier I, Servant N, Boland A, Mazoyer S, Deleuze JF, Stoppa-Lyonnet D, Andrieu N, Lesueur F

Int. J. Cancer. 2018 Oct 10;:

Breast cancer (BC) treatment (tx) with everolimus (EVE) and exemestane (EXE) in hormone receptor positive (HR+)/ HER2-negative (HER2-) postmenopausal women: Final analysis of the French observational TANGO study.

Villanueva C, Yazbek G, Beuzeboc P, Viel E, Dohollou N, Luporsi E, Eymard JC, Levy E, Mouret-Reynier MA, Dourthe LM, Malaurie E, Madelenat M, Denden A, Antoine EC

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii109

[PALB2, a major susceptibility gene for breast cancer].

Piffer A, Luporsi E, Mathelin C

Gynecol Obstet Fertil Senol. 2018 Sep 19;:

Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations.

Pujol P, Perre PV, Faivre L, Sanlaville D, Corsini C, Baertschi B, Anahory M, Vaur D, Olschwang S, Soufir N, Bastide N, Amar S, Vintraud M, Ingster O, Richard S, Le Coz P, Spano JP, Caron O, Hammel P, Luporsi E, Toledano A, Rebillard X, Cambon-Thomsen A, Putois O, Rey JM, Hervé C, Zorn C, Baudry K, Galibert V, Gligorov J, Azria D, Paillerets BB, Burnichon N, Spielmann M, Zarca D, Coupier I, Cussenot O, Gimenez-Roqueplo AP, Giraud S, Lapointe AS, Niccoli P, Raingeard I, Le Bidan M, Frebourg T, Rafii A, Geneviève D

Eur. J. Hum. Genet.. 2018 Aug 8;:

Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation.

El Tannouri R, Albuisson E, Jonveaux P, Luporsi E

Fam. Cancer. 2018 Mar 17;:

Is there a genetic anticipation in breast and/or ovarian cancer families with the germline c.3481_3491del11 mutation?

El Tannouri R, Albuisson E, Jonveaux P, Luporsi E

Fam. Cancer. 2017 May;:

Prevalence and incidence of chronic pain with or without neuropathic characteristics in patients with cancer.

Bouhassira D, Luporsi E, Krakowski I

Pain. 2017 Mar;:

Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study).

Luporsi E, Toledano A, Spaeth D, Scotté F, Espié M, Perot S, Duvillié L, Pithois Merli I, Bugat R

Support Care Cancer. 2017 Mar;25(3):973-982

[Breast cancer management: The change is now!]

Mathelin C, Luporsi E

Gynecol Obstet Fertil Senol. 2017 Jan;45(1):3-4

Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients.

Kurtz JE, Soubeyran P, Michallet M, Luporsi E, Albrand H

Onco Targets Ther. 2016 ;9:6689-6693

GENESIS: a French national resource to study the missing heritability of breast cancer.

Sinilnikova OM, Dondon MG, Eon-Marchais S, Damiola F, Barjhoux L, Marcou M, Verny-Pierre C, Sornin V, Toulemonde L, Beauvallet J, Le Gal D, Mebirouk N, Belotti M, Caron O, Gauthier-Villars M, Coupier I, Buecher B, Lortholary A, Dugast C, Gesta P, Fricker JP, Noguès C, Faivre L, Luporsi E, Berthet P, Delnatte C, Bonadona V, Maugard CM, Pujol P, Lasset C, Longy M, Bignon YJ, Adenis C, Venat-Bouvet L, Demange L, Dreyfus H, Frenay M, Gladieff L, Mortemousque I, Audebert-Bellanger S, Soubrier F, Giraud S, Lejeune-Dumoulin S, Chevrier A, Limacher JM, Chiesa J, Fajac A, Floquet A, Eisinger F, Tinat J, Colas C, Fert-Ferrer S, Penet C, Frebourg T, Collonge-Rame MA, Barouk-Simonet E, Layet V, Leroux D, Cohen-Haguenauer O, Prieur F, Mouret-Fourme E, Cornélis F, Jonveaux P, Bera O, Cavaciuti E, Tardivon A, Lesueur F, Mazoyer S, Stoppa-Lyonnet D, Andrieu N

BMC Cancer. 2016 Jan;16:13

Mutation analysis of PALB2 gene in French breast cancer families.

Damiola F, Schultz I, Barjhoux L, Sornin V, Dondon MG, Eon-Marchais S, Marcou M, Caron O, Gauthier-Villars M, de Pauw A, Luporsi E, Berthet P, Delnatte C, Bonadona V, Maugard C, Pujol P, Lasset C, Longy M, Bignon YJ, Fricker JP, Andrieu N, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Muller D

Breast Cancer Res Treat. 2015 Nov 12.

[uPA/PAI-1, Oncotype DX, MammaPrint((R)). Prognosis and predictive values for clinical utility in breast cancer management].

Luporsi E, Bellocq JP, Barriere J, Bonastre J, Chetritt J, Le Corroller AG, de Cremoux P, Fina F, Gauchez AS, Lamy PJ, Martin PM, Mazouni C, Peyrat JP, Romieu G, Verdoni L, Mazeau-Woynar V, Kassab-Chahmi D

Bull Cancer. 2015 Sep;102(9):719-29

Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France.

Toledano A, Luporsi E, Morere JF, Scotte F, Laribi K, Barriere J, Huot-Marchand P, Duvillie L, Concas VH, Bugat R

Support Care Cancer. 2015 Apr 29.

Breast cancer risk associated with oestrogen exposure and truncating mutation location in BRCA1/2 carriers.

Lecarpentier J, Nogues C, Mouret-Fourme E, Buecher B, Gauthier-Villars M, Stoppa-Lyonnet D, Bonadona V, Fricker JP, Berthet P, Caron O, Coupier I, Pujol P, Faivre L, Gesta P, Eisinger F, Mari V, Gladieff L, Lortholary A, Luporsi E, Leroux D, Venat-Bouvet L, Maugard CM, Colas C, Tinat J, Lasset C, Andrieu N

Cancer Epidemiol Biomarkers Prev. 2015 Jan 22. pii: cebp.0884.2014.

[uPA/PAI-1, Oncotype DX, MammaPrint((R)). Prognosis and predictive values for clinical utility in breast cancer management].

Bellocq JP, Luporsi E, Barriere J, Bonastre J, Chetritt J, Le Corroller AG, de Cremoux P, Fina F, Gauchez AS, Kassab-Chahmi D, Lamy PJ, Martin PM, Mazouni C, Peyrat JP, Romieu G, Verdoni L, Mazeau-Woynar V

Ann Pathol. 2014 Oct;34(5):349-51

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.

Bonnefoi H, Litiere S, Piccart M, MacGrogan G, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Moldovan C, Bodmer A, Zaman K, Cufer T, Campone M, Luporsi E, Malmstrom P, Werutsky G, Bogaerts J, Bergh J, Cameron DA

Ann Oncol. 2014 Jun;25(6):1128-36

uPA/PAI-1, Oncotype DX (TM), MammaPrintA (R) Prognosis and predictive values for clinical utility in breast cancer management.

Luporsi E, Bellocq JP, Barriere J, Bonastre J, Chetritt J, Le Corroller AG, de Cremoux P, Fina F, Gauchez AS, Lamy PJ, Martin PM, Mazouni C, Peyrat JP, Romieu G, Verdoni L, Mazeau-Woynar V, Kassab-Chahmi D

Oncologie. 2014 Apr;16(4):196-206.

BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study.

Michallet M, Luporsi E, Soubeyran P, Amar NA, Boulanger V, Carreiro M, Dourthe LM, Labourey JL, Lepille D, Maloisel F, Mouysset JL, Nahon S, Narciso B, Nouyrigat P, Radji R, Sakek N, Albrand H

BMC Cancer. 2014 Jul 10;14:503

French women's breast self-examination practices with time after undergoing BRCA1/2 genetic testing.

Maheu C, Apostolidis T, Petri-Cal A, Mouret-Fourme E, Gauthier-Villars M, Lasset C, Berthet P, Fricker JP, Caron O, Luporsi E, Gladieff L, Nogues C, Julian-Reynier C

Fam Cancer. 2012 Jun;11(2):269-78

Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial.

Peiffert D, Tournier-Rangeard L, Gérard JP, Lemanski C, François E, Giovannini M, Cvitkovic F, Mirabel X, Bouché O, Luporsi E, Conroy T, Montoto-Grillot C, Mornex F, Lusinchi A, Hannoun-Lévi JM, Seitz JF, Adenis A, Hennequin C, Denis B, Ducreux M

J. Clin. Oncol.. 2012 Jun;30(16):1941-8

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.

Luporsi E, Andre F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A, Egele C, Poulet B, Clough KB, Crouet H, Fourquet A, Lefranc JP, Mathelin C, Rouyer N, Serin D, Spielmann M, Haugh M, Chenard MP, Brain E, de Cremoux P, Bellocq JP

Breast Cancer Res Treat. 2012 Apr;132(3):895-915

Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO).

Lecarpentier J, Nogues C, Mouret-Fourme E, Gauthier-Villars M, Lasset C, Fricker JP, Caron O, Stoppa-Lyonnet D, Berthet P, Faivre L, Bonadona V, Buecher B, Coupier I, Gladieff L, Gesta P, Eisinger F, Frenay M, Luporsi E, Lortholary A, Colas C, Dugast C, Longy M, Pujol P, Tinat J, Lidereau R, Andrieu N

Breast Cancer Res. 2012 Jul 3;14(4):R99

70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial.

Beckendorf V, Guerif S, Le Prise E, Cosset JM, Bougnoux A, Chauvet B, Salem N, Chapet O, Bourdain S, Bachaud JM, Maingon P, Hannoun-Levi JM, Malissard L, Simon JM, Pommier P, Hay M, Dubray B, Lagrange JL, Luporsi E, Bey P

Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1056-63

Prevalence and treatment management of oropharyngeal candidiasis in cancer patients: results of the French CANDIDOSCOPE study.

Gligorov J, Bastit L, Gervais H, Henni M, Kahila W, Lepille D, Luporsi E, Sasso G, Varette C, Azria D

Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):532-9

Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations.

Julian-Reynier C, Mancini J, Mouret-Fourme E, Gauthier-Villars M, Bonadona V, Berthet P, Fricker JP, Caron O, Luporsi E, Nogues C

Eur J Hum Genet. 2011 May;19(5):500-6

Oropharyngeal candidiasis (OPC) and solid tumors.

Gligorov J, Ben Slama L, Dellamonica P, Demard F, Gangneux JP, Huttenberger B, Serin D, Luporsi E, Spielmann M, Falandry C, Cure H, Moureau-Zabotto L, Barry B, Namer M

. 2011 Apr;13(4):167-74.

Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics.

Julian-Reynier C, Bouhnik AD, Mouret-Fourme E, Gauthier-Villars M, Berthet P, Lasset C, Fricker JP, Caron O, Gesta P, Luporsi E, Faivre L, Longy M, Gladieff L, Frenay M, Dreyfus H, Sobol H, Vennin P, Nogues C

Genet Med. 2010 Dec;12(12):801-7.

Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO).

Rousseau F, Retornaz F, Joly F, Esterni B, Abadie-Lacourtoisie S, Fargeot P, Luporsi E, Servent V, Laguerre B, Brain E, Geneve J

Crit Rev Oncol Hematol. 2010 Oct;76(1):71-8

Estramustine: what is its place in 2010 in metastatic breast cancer?

Luporsi E, Guastalla JP, Medioni J, Namer M, Spielmann M, Toledano A, Gligorov J, Dourthe LM

Oncologie. 2010 Jun;12(5-6):341-8

2009 Report on the state of knowledge of tissular biomarkers uPA-PAI-1, Oncotype DX (TM) and Mammaprint (R) in breast cancer care

Luporsi E, Andre F, Bellocq JP, Caron Y, Fumoleau P, Gompel A, Martin PM, Roche H, Salmon R, Sigal-Zafrani B, Spyratos F, Kassab-Chahmi D, Bosquet L, Mazeau-Woynar V

Oncologie. 2010 Feb;12(2):158-63

Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged

Largillier R, Savignoni A, Gligorov J, Chollet P, Guilhaume MN, Spielmann M, Luporsi E, Asselain B, Coudert B, Namer M

Cancer. 2009 Nov 15;115(22):5155-65.

[Cancer genetics: estimation of the needs of the population in France for the next ten years]

Bonaiti-Pellie C, Andrieu N, Arveux P, Bonadona V, Buecher B, Delpech M, Jolly D, Julian-Reynier C, Luporsi E, Nogues C, Nowak F, Olschwang S, Orsi F, Pujol P, Saurin JC, Sinilnikova O, Stoppa-Lyonnet D, Thepot F

Bull Cancer. 2009 Sep;96(9):875-900.

[Methodological aspects on new protocols in oncology]

Luporsi E

Bull Cancer. 2008 Oct;95(10):979-83.

[The use of deodorants/antiperspirants does not constitute a risk factor for breast cancer]

Namer M, Luporsi E, Gligorov J, Lokiec F, Spielmann M

Bull Cancer. 2008 Oct 1;95(9):871-80.

Therapeutic strategies in the metastatic phase: St. Paul de Vence on a daily basis

Luporsi E, Dohollou N, Zelek L, Legouffe E

Oncologie. 2008 Mar;10 Suppl. 3:S50-6

Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study.

Chang-Claude J, Andrieu N, Rookus M, Brohet R, Antoniou AC, Peock S, Davidson R, Izatt L, Cole T, Nogues C, Luporsi E, Huiart L, Hoogerbrugge N, Van Leeuwen FE, Osorio A, Eyfjord J, Radice P, Goldgar DE, Easton DF

Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):740-6.

Metastatic breast cancer: therapeutic strategies

Luporsi E

Oncologie. 2007 Mar;9 Suppl. 1:S2-8

[Patient information booklet SOR SAVOIR PATIENT: understanding ovarian cancer, a guide for cancer patients and family members].

Hoarau H, Kerbrat P, Lesoin A, Lhomme C, Luporsi E, Philip T, Querleu D, Saltel P, Thomas L, Vennin P, Veron M, Voigt JJ

Gynecol Obstet Fertil. 2006 Dec;34(12):1195-204

Epirubicin-based chemotherapy as adjuvant treatment for poor prognosis, node-negative breast cancer: 10-year follow-up results of the French Adjuvant Study Group 03 trial.

Hery M, Bonneterre J, Roche H, Luporsi E, Kerbrat P, Namer M, Fumoleau P, Monnier A, Fargeot P

Bull Cancer. 2006 Oct 1;93(10):E109-14.

[Role for aromatase inhibitors as adjuvant treatment of breast cancer in menopaused women: facts and questions in 2005].

Lesur A, Cutuli B, Teissier MP, Luporsi E

J Gynecol Obstet Biol Reprod (Paris). 2006 Jun;35(4):327-40.

Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02

Namer M, Fargeot P, Roche H, Campone M, Kerbrat P, Romestaing P, Monnier A, Luporsi E, Montcuquet P, Bonneterre J

Ann Oncol. 2006 Jan;17(1):65-73.

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.

Fumoleau P, Roche H, Kerbrat P, Bonneterre J, Romestaing P, Fargeot P, Namer M, Monnier A, Montcuquet P, Goudier MJ, Luporsi E

Ann Oncol. 2006 Jan;17(1):85-92

Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study.

Bernier-Chastagner V, Grill J, Doz F, Bracard S, Gentet JC, Marie-Cardine A, Luporsi E, Margueritte G, Lejars O, Laithier V, Mechinaud F, Millot F, Kalifa C, Chastagner P

Cancer. 2005 Dec 15;104(12):2792-7.

[Standards, Options and Recommendations for the management of ductal carcinoma in situ of the breast (DCIS): update 2004].

Cutuli B, Fourquet A, Luporsi E, Arnould L, Caron Y, Cremoux P, Dilhuydy JM, Fondrinier E, Fourme E, Giard-Lefevre S, Blanc-Onfroy ML, Lemanski C, Mauriac L, Sigal-Zafrani B, Tardivon A, This P, Tunon de Lara C, Kirova Y, Fabre N

Bull Cancer. 2005 Feb;92(2):155-68.

[Preoperative brachytherapy for clinical stage I and II endometrial carcinoma: results from a series of 780 patients with a 10-year follow-up].

Hoffstetter S, Brunaud C, Marchal C, Luporsi E, Guillemin F, Leroux A, Bey P, Peiffert D

Cancer Radiother. 2004 Jun;8(3):178-87

Summary version of the Standards, Options and Recommendations for nonmetastatic breast cancer (updated January 2001).

Mauriac L, Luporsi E, Cutuli B, Fourquet A, Garbay JR, Giard S, Spyratos F, Sigal-Zafrani B, Dilhuydy JM, Acharian V, Balu-Maestro C, Blanc-Vincent MP, Cohen-Solal C, De Lafontan B, Dilhuydy MH, Duquesne B, Gilles R, Lesur A, Shen N, Cany L, Dagousset I, Gaspard MH, Hoarau H, Hubert A, Monira MH, Perrie N, Romieu G

Br J Cancer. 2003 Aug;89 Suppl 1:S17-31.

Quality of life in long-term survivors of oropharynx carcinoma.

Pourel N, Peiffert D, Lartigau E, Desandes E, Luporsi E, Conroy T

Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):742-51.

High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study.

Peiffert D, Giovannini M, Ducreux M, Michel P, Francois E, Lemanski C, Mirabel X, Cvitkovic F, Luporsi E, Conroy T, Gerard JP

Ann Oncol. 2001 Mar;12(3):397-404.

6 cycles of FEC100 vs 6 cycles of epirubicin-docetaxel as neoadjuvant chemotherapy in operable breast cancer patients : preliminary results of a randomized phase II trial of GIREC S01.

Luporsi E, Vanlemmens L, Coudert B

Cancer Conference Highlights 2000;4:2-4.

Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer.

Kaminsky-Forrett MC, Conroy T, Luporsi E, Peiffert D, Lapeyre M, Boissel P, Guillemin F, Bey P

Int. J. Radiat. Oncol. Biol. Phys.. 1998 Dec;42(5):935-41

[Interstitial brachytherapy in infiltrating cancer of the bladder. The Nancy experience].

Hoffstetter S, Hubert J, Guillemin F, Peiffert D, Marchal C, Luporsi E, Pernot M

Cancer Radiother. 1998 Apr;2 Suppl 1:54s-61s

Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications.

Peiffert D, Bey P, Pernot M, Guillemin F, Luporsi E, Hoffstetter S, Aletti P, Boissel P, Bigard MA, Dartois D, Baylac F

Int. J. Radiat. Oncol. Biol. Phys.. 1997 Jan;37(2):313-24

Combined surgery and brachytherapy in the treatment of some cancers of the bladder (partial cystectomy and interstitial iridium-192).

Pernot M, Hubert J, Guillemin F, Six A, Hoffstetter S, Peiffert D, Verhaeghe J, Luporsi E

Radiother Oncol. 1996 Feb;38(2):115-20

[Axillary lymphoceles after breast cancer surgery. Pathogeny, prevention].

Rauch P, De la Chapelle AL, Meunier A, Luporsi E, Guillemin F

J Chir (Paris). 1996 ;133(9-10):448-52

Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities.

Barberi-Heyob M, Weber B, Merlin JL, Dittrich C, de Bruijn EA, Luporsi E, Guillemin F

Cancer Chemother. Pharmacol.. 1995 ;37(1-2):110-6

Pre-operative, post-operative and exclusive irradiation of endometrial adenocarcinoma.

Pernot M, Hoffstetter S, Peiffert D, Guillemin F, Carolus JM, Verhaeghe JL, Luporsi E, Beckendorf V

Strahlenther Onkol. 1994 Jun;170(6):313-21

Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma.

Conroy T, Geoffrois L, Guillemin F, Luporsi E, Krakowski I, Spaëth D, Frasie V, Volff D

Cancer. 1993 Oct;72(7):2190-7

[Mixed mullerian tumours of the endometrium. Retrospective study, with prognostic aims, comparing their evolution to that of adenocarcinomas of the endometrium].

Peiffert D, Pernot M, Guillemin F, Luporsi E, Parache RM, Legras B, Bey P

J Gynecol Obstet Biol Reprod (Paris). 1991 ;20(7):933-40

[Conservative treatment of breast cancer. Carcinologic and cosmetic results of combination quadrantectomy and irradiation at the Centre Alexis-Vautrin].

Langlois D, Allavena C, Carolus JM, Luporsi E, Barlier-Pagel C, Bey P, Guillemin F, Stines J, Weber B

Bull Cancer. 1989 ;76(4):353-60

[Low-dose postoperative vaginal brachytherapy of adenocarcinoma of the endometrium].

Charra-Brunaud C, Peiffert D, Hoffstetter S, Luporsi E, Guillemin F, Bey P

Cancer Radiother. ;2(1):34-41

Fiche personne

Coordonnées

Territoire

Statut

Affiliation

Équipes/plateformes

Recherche

Publications

Retrouvez aussi